Ifm_05-may 2022 -

If you are looking for guidance based on this study's results:

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods. IFM_05-May 2022

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. If you are looking for guidance based on

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations IFM_05-May 2022

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.